JaLCDOI 10.18926/AMO/58279
FullText URL 74_2_179.pdf
Author Abe, Yoshiyuki| Fujibayashi, Kazutoshi| Nishizaki, Yuji| Yanagisawa, Naotake| Nojiri, Shuko| Kon, Takayuki| Tada, Kurisu| Yamaji, Ken| Tamura, Naoto|
Abstract Glucocorticoids (GCs) have long played a central role in the treatment of systemic lupus erythematosus (SLE), but these drugs have many adverse effects. We will determine whether rapid weekly GC tapering is non-inferior to conventional biweekly tapering in patients with severe SLE. This is a randomized, open-label, multicenter controlled trial. The primary outcome is the relapse-free survival rate at 52 weeks. The main secondary outcome is the prevalence of the Lupus Low Disease Activity State at 52 weeks. The trial will determine the optimal method of tapering GCs in patients with severe SLE.
Keywords systemic lupus erythematosus relapse-free survival rate glucocorticoid, tapering Lupus Low Disease Activity State
Amo Type Clinical Study Protocol
Published Date 2020-04
Publication Title Acta Medica Okayama
Volume volume74
Issue issue2
Publisher Okayama University Medical School
Start Page 179
End Page 183
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2020 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 32341595
Web of Science KeyUT 000528278500014
JaLCDOI 10.18926/AMO/56464
FullText URL 73_1_85.pdf
Author Abe, Yoshiyuki| Fujibayashi, Kazutoshi| Nishizaki, Yuji| Yanagisawa, Naotake| Nojiri, Shuko| Nakano, Soichiro| Tada, Kurisu| Yamaji, Ken| Tamura, Naoto|
Abstract Pneumocystis pneumonia (PCP) due to Pneumocystis jirovecii infection is the leading cause of fatal opportunistic infections in immunocompromised patients. We will determine whether a daily sulfamethoxazole-trimethoprim (SMX/TMP) dose of 200/40 mg was non-inferior to 400/80 mg for PCP prevention in patients with systemic rheumatic disease under immunosuppressive therapy. This is a randomized, open-label, multicenter controlled trial. The primary outcome is the rate of PCP prevention at 52 weeks. The secondary outcome is the discontinuation rate of SMX/TMP. The trial will evaluate the optimal dose of SMX/TMP for PCP prevention in patients with systemic rheumatic disease under immunosuppressive therapy.
Keywords pneumocystis pneumonia prophylaxis systemic rheumatic disease sulfamethoxazole-trimethoprim conventional-dose versus half-dose
Amo Type Clinical Study Protocol
Published Date 2019-02
Publication Title Acta Medica Okayama
Volume volume73
Issue issue1
Publisher Okayama University Medical School
Start Page 85
End Page 89
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders CopyrightⒸ 2019 by Okayama University Medical School
File Version publisher
Refereed True
PubMed ID 30820060